TABLE 1

Serotype distribution for each study year, 2009 to 2017, in adults ≥18 years of age

SerotypeNo. of isolates per yrPreVac isolates (2009–2011)PostVac-I isolates (2012–2014)PreVac vs PostVac-I p valuePostVac-II isolates (2015–2017)PreVac vs PostVac-II p value
200920102011201220132014201520162017No.No. per 100,000No.No. per 100,000No.No. per 100,000
311959386772514.72011.30.5582010.70.485
400100010010.600Nca10.50.965
6A10445401111810.695.10.22131.60.016
6B910211733312112.32111.80.92773.70.052
6C01011027510.621.10.719147.50.021
7F02010020021.210.60.68321.10.951
801000000010.600Nc00Nc
9V34220000095.321.10.13600Nc
9A10101100021.221.10.97700Nc
9N01000211210.621.10.13642.1Nc
1000100000010.600Nc00Nc
11A563263749148.2116.20.6412010.70.617
14870331001158.873.90.22910.50.008
15A11013122421.252.80.47084.30.230
15B/C30535346184.7116.20.694115.90.749
16F23011001052.921.10.42610.50.231
17F00100100010.610.60.98400Nc
18B00100000010.600Nc00Nc
18C20000000021.200Nc00Nc
19F3045242923151118b9958.26737.70.06820b10.7<0.001
19A532346453105.9137.30.730126.40.891
2000100000010.600Nc00Nc
2110011011410.621.10.71963.20.217
22F435513541127.195.10.619105.40.670
23F81177442002615.3158.50.21921.10.001
23A30011252631.842.30.832137.00.111
23B01302354142.452.80.859105.40.337
24F0000001100000Nc21.1Nc
3101000000010.600Nc00Nc
33F21130011042.431.70.77421.10.536
3410000010010.600Nc10.50.965
35F01133413321.2105.60.12373.70.298
35B21341237463.573.90.895147.50.289
Not determinedc01001200410.631.70.51842.10.396
NESpd256478111311137.61910.70.5343518.70.054
Total11312279998272707486314184.7253142.50.043230123.20.002
VTe5977345337239420170100.011363.70.0133317.7<0.001
NVTf54454546454961706614484.714078.90.693197105.50.184
All LRT samples2,1531,9761,6761,7501,6711,6202,1762,3842,3565,8053,413.95,0412,840.2<0.0016,9163,703.90.003
Percentage of LRT samples positive for pneumococci5.26.24.75.74.94.43.23.13.75.45.03.3
  • a Nc, not calculated.

  • b Seven isolates of serotype 19F were detected in the same patient in 2017.

  • c Serotypes other than those included in the multiplex PCR panel of the study.

  • d NESp, nonencapsulated S. pneumoniae.

  • e Serotypes detected in the study that are targeted by PHiD-CV (4, 6B, 7F, 9V, 14, 18C, 19F, and 23F).

  • f Serotypes detected in the study that are not targeted by PHiD-CV.